Silexion Therapeutics prices public offering of shares and warrants at $1.35 per share

From GlobeNewswire: 2025-01-15 20:00:00

Silexion Therapeutics Corp (NASDAQ: SLXN) announced the pricing of a public offering of 3,703,703 ordinary shares and warrants at $1.35 per share. H.C. Wainwright & Co. is the exclusive placement agent, with expected gross proceeds of $5.0 million. The net proceeds will advance pre-clinical studies and general corporate purposes. The offering is expected to close on January 17, 2025, subject to customary conditions. The securities are offered under a registration statement on Form S-1. Silexion Therapeutics focuses on developing RNA interference therapies for KRAS-driven cancers, with promising results in its LODER™ product for non-resectable pancreatic cancer.

For more information about Silexion Therapeutics, visit their website at https://silexion.com. This press release contains forward-looking statements regarding the completion of the offering and use of net proceeds. Silexion cautions against placing undue reliance on these statements, as actual results may differ due to various factors. These include the company’s ability to complete preclinical studies, regulatory impact, future partnerships, and capital requirements. Silexion will update forward-looking statements as needed. For inquiries, contact Silexion Therapeutics Corp or Arx | Capital Markets Advisors.



Read more at GlobeNewswire: Silexion Therapeutics Announces Pricing of $5.0 Million